Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc demonstrated a strong financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, which marked a significant 105% increase from the previous quarter. The company's gross margins also showed improvement, rising to 60.3%, compared to 39.8% in the prior quarter, indicating enhanced operational efficiency. Moreover, the announcement of a non-binding merger agreement with Applied Digital Cloud suggests potential strategic growth opportunities, further contributing to a positive outlook for the company.

Bears say

Ekso Bionics Holdings Inc experienced a revenue miss in the prior quarter, attributed to two significant order delays in enterprise sales that collectively accounted for $1.5 million. In the third quarter of 2025, the company reported revenues of $4.23 million alongside a net loss of $0.54 per share, revealing only a marginal improvement compared to consensus estimates of $4.16 million in revenue and a higher net loss of $0.96 per share. These factors, combined with the management's decision to downgrade the stock rating to Neutral, underscore a negative outlook on the company's financial performance and growth potential.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.